Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 13 Multiple Myeloma 6 Lymphoma 5 Lung Neoplasms 5 Melanoma 3 Hematologic Neoplasms 3 Uveal Melanoma 2 Stomach Neoplasms 2 Colorectal Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neurofibromatosis 2 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 2a 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1 Glioma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Endometrial Cancer Recurrent 1 Colonic Neoplasms 1

Interventions

HDAC-42 2 Bevacizumab 2 temsirolimus 1 neratinib 1 brigatinib 1 Valproic Acid 1 Sirolimus 1 Immunoglobulin G 1 Doxycycline 1 Disulfides 1 Crizotinib 1 Cetuximab 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatosis 2 × Crizotinib × 1 year × Clear all

NCT04283669 2026-03-13

NF110

University of Alabama at Birmingham

Phase 2 Completed

12 enrolled 5 charts

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡